[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renal-cancer":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,46,0,25,[9,51,77,115,174,213,234,261,292,326,350,376,405,432,453,490,519,549,574,599,630,661,682,708,730],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":4,"leadSponsor":47,"locationsCount":50},"100141241","comprehensive-omics-analysis-of-pediatric-and-adult-solid-tumors-and-establishment-of-a-repository-for-related-biological-studies-100141241",false,"NCT01109394","Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies","* SUBJECT INCLUSION CRITERIA:\n\nPediatric or adult subjects with one of the following:\n\n* Diagnosis of any tumor, malignancy, pre-malignant disorder, or suspected premalignant familial syndromes, regardless, of patient age;\n* Biological relatives of any patient with a tumor, malignancy, pre-malignant disorder, or suspected familial pre-malignant syndrome, regardless of patient age or the diagnosis of an adult malignancy or pre-malignant disorder;\n* Healthy Volunteer without history of malignancy nor a family member currently being treated for cancer who are undergoing surgery, treatment or during well visits;\n* Biospecimens can be collected with minimal additional risk to the subject during sampling or procedures required for routine patient care.\n* Human samples, specimens and data collected on IRB approved protocols that are now closed\n* Ability of subject, Legally Authorized Representative (LAR), or parent\u002Flegal guardian of children \\\u003C=18 to understand and be willing to sign an IRB-approved informed consent document that permits the use of the tumor and other samples for genomic-based molecular characterization projects.\n\nInclusion Criteria for Social and Behavioral Outcome Interviews:\n\n* Parent\u002Fcaregiver of a participating pediatric or adult patient who is being treated for, or who has previously been treated for any form of pediatric cancer.\n* Must be able to give consent and sign the informed consent document.\n* Able to understand the English language.\n\nEXCLUSION CRITERIA:\n\nNone",true,"ALL","4 Weeks",{"count":20,"type":21},6035,"ESTIMATED","OBSERVATIONAL","Background:\n\n\\- Laboratory investigators who are studying common childhood cancers are interested in developing a tissue repository to collect and store blood, serum, tissue, urine, or tumors of children who have cancer or adults who have common childhood cancers. To develop this repository, additional samples will be collected from children and adults who have been diagnosed with common childhood cancers such as leukemia and tumors of the central nervous system.\n\nObjectives:\n\n\\- To collect and store blood, serum, tissue, urine, or tumor samples of children who have cancer or adults who have common childhood cancers.\n\nEligibility:\n\n* Individuals who have been diagnosed with a common childhood cancer (e.g., leukemia) regardless of patient age.\n* Children, adolescents, and adults who have been diagnosed with a type of cancer more commonly found in adults.\n\nDesign:\n\n* Extra blood, serum (the liquid part of blood), tissue, urine, or tumor samples will be collected from participants at a time when sampling is required for medical care or as part of a research study.\n* No additional procedures will be performed for the sole purpose of obtaining additional tumor tissue, aside from what is required for clinical care.",[25,26,27,28,29],"Sarcoma","Endocrine Tumors","Neuroblastoma","Retinoblastoma","Renal Cancer",[31,32,33,34,35,36,37,38,25,39,27],"Genomics","Proteomics","Tissue Repository","Omics","Cell Lines","Natural History","Pediatric Cancer","Solid Tumor","Kidney Cancer","RECRUITING","2026-06-23",{"date":43,"type":44},"2026-06-24","ACTUAL",{"date":46,"type":44},"2010-04-21",{"name":48,"class":49},"National Cancer Institute (NCI)","NIH",5,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":16,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":72,"startDateStruct":73,"completionDateStruct":4,"leadSponsor":75,"locationsCount":76},"100060106","collection-of-serum-and-tissue-samples-from-patients-with-biopsy-proved-or-suspected-malignant-disease-100060106","NCT00026884","Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease","Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Diseases","* INCLUSION CRITERIA:\n* Individuals with biopsy-proven malignant disease\n* Individuals suspected of having a malignant disease\n* Individuals who have or are suspected of having an inherited genitourinary malignant disorder\n* Participants must be \\>= 2 years of age\n* A relative (related by blood) of an individual with a confirmed or suspected diagnosis of a malignant disease or an inherited genitourinary malignant disorder.\n* All participants and parents\u002Fguardians, for children younger than 18 years of age, must sign an informed consent document indicating their understanding of the investigational nature and the risks of this study before any protocol related studies are performed.\n\nEXCLUSION CRITERIA:\n\n-Individuals whose co-morbidities preclude surgical intervention.","2 Years",{"count":60,"type":21},5950,"Selected individuals suspected of having or with prior biopsy proof of malignant disease will be seen in the Urologic Oncology Branch, NCI. Blood samples may be collected at the time of the initial visit and at periodic intervals during the course of the disease. These samples will be stored in the tissue bank of the Urologic Oncology Branch. Aliquots of malignant and normal tissue will be collected at the time of surgery and stored in the tissue bank, Urologic Oncology Branch, NCI. These materials will be used in the research efforts of the Urologic Oncology Branch, NCI....",[63,64,39,29,65],"Malignant Neoplasms","Hereditary Neoplastic Syndromes","Bladder Cancer",[67,68,69,70,71,36],"Serum","Collection of Tissue","Malignant Disease","Molecular Basis","Genome Sequencing",{"date":43,"type":44},{"date":74,"type":44},"1998-03-12",{"name":48,"class":49},1,{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":101,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":76},"100590480","research-of-double-positive-circulating-cells-tumor-marker--cd45-in-several-types-of-metastatic-cancers-100590480","NCT06967961","Research of Double-positive Circulating Cells (Tumor Marker \u002F CD45+) in Several Types of Metastatic Cancers","DP-PAN-CANCER","Inclusion Criteria:\n\n* 1\\. Patients with one of the following cancer types: urothelial carcinoma, renal carcinoma, prostate adenocarcinoma, upper aerodigestive tract carcinoma, cervival carcinoma, adenocarcinoma of endometrium, cutaneous melanoma, soft tissue sarcoma, seminomatous and nonseminomatous germ cell tumors\n* 2\\. Metastatic disease for which the treatment (whatever the line) has not been initiated yet\n* 3\\. Age ≥ 18 years\n* 4\\. Patient affiliated to a French Social Security scheme\n* 5\\. Patient having signed his\u002Fher informed consent prior to inclusion in the study and prior to any specific procedure for the study.\n\nExclusion Criteria:\n\n* 1\\. Patient with localized disease.\n* 2\\. Pregnant or breast-feeding women.\n* 3\\. Any psychological, family, geographical or sociological condition that prevents compliance with the medical monitoring and\u002For procedures set out in the study protocol.\n* 4\\. Patient who has forfeited his\u002Fher freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).","18 Years",{"count":86,"type":21},450,"INTERVENTIONAL",[89],"NA","A prospective, proof-of-concept pilot study in patients with metastatic cancers (9 types of cancers are studied) treated at the IUCT-O or possibly in other institutions. Eligible patients will be selected and informed of this study during a medical consultation for their cancer by medical oncologists. Then, with the patient's consent and before the start of anti-cancer treatment (whatever the line), a blood sample will be taken to detect DP-circulating cells by 2 different methods of analysis.\n\nEach patient will participate in the study for one day. The methods of analysis will be: flow cytometry for all patients and either Parsotix® or CellSearch® depending on the type of cancer.\n\n450 patients will be enrolled in total.",[92,29,93,94,95,96,97,98,99,100],"Urothelial Carcinoma","Prostate Adenocarcinoma","Adenocarcinoma of Endometrium","Cutaneous Melanoma","Soft Tissue Sarcoma (STS)","Nonseminomatous Germ Cell Tumor","Seminomatous Germ Cell Tumor","Upper Aerodigestive Tract Carcinoma","Cervical Carcinoma",[102,103,104],"metastatic cancers","Double Positive Circulating cells","liquid biopsy","2026-06-12",{"date":107,"type":44},"2026-06-15",{"date":109,"type":44},"2025-07-23",{"date":111,"type":21},"2029-07-23",{"name":113,"class":114},"Institut Claudius Regaud","OTHER",{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":123,"targetDuration":125,"studyType":22,"phases":4,"briefSummary":126,"conditions":127,"keywords":140,"overallStatus":163,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":173},"100642988","registry-of-minimally-invasive-cancer-treatment-using-spectral-angio-ct-image-guidance-100642988","NCT07636148","Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance","Prospective Registry of Spectral Angio-CT-Guided Interventional Oncology Procedures in Routine Clinical Practice","PreciseOnco","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Undergoing a clinically indicated IO procedure with a percutaneous or transarterial approach for solid tumors;\n* Use of spectral angio-CT image guidance as part of standard care;\n* Written confirmed consent.\n\nExclusion Criteria:\n\n* Patients who are declared incapacitated;\n* Patients suffering from psychic disorders that make a comprehensive judgement impossible.",{"count":124,"type":21},2000,"3 Years","This study collects data from patients undergoing minimally invasive, image-guided cancer treatments at participating hospitals in the Netherlands and France. All treatments are performed as standard clinical care and include procedures such as tumor ablation and catheter-based treatments of cancer in the liver, kidney, lung, and bone.\n\nDuring these procedures, a spectral angio-CT system is used for image guidance. This advanced CT scanner automatically captures additional imaging information beyond what is used in routine clinical decision-making. The goal of this study is to investigate how this additional imaging information is associated with treatment outcomes, and how it can be used in the future to improve treatment planning, procedural guidance, and prediction of treatment results.\n\nNo experimental interventions are performed. Participation does not alter the treatment or follow-up patients receive. Data are collected from medical records and imaging systems and stored securely for analysis.",[128,129,130,131,132,29,133,134,135,136,137,138,139],"Liver Cancer (Primary and Metastatic)","Lung Cancer (Diagnosis)","Bone Cancer Metastatic","Bone Cancer Tumor","Kidney Tumors","Hepatocellular Carcinoma (HCC)","Renal Cell Carcinoma (Kidney Cancer)","Renal Cell Carcinoma (RCC)","Musculoskeletal Cancers","Musculoskeletal Tumors","Bone Tumors","Lung Tumors",[141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162],"Spectral CT","Dual-layer detector CT","Angio-CT","Image-guided therapy","Interventional oncology","Thermal ablation","Radiofrequency ablation","Microwave ablation","Cryoablation","Transarterial chemoembolization","Transarterial radioembolization","Transarterial embolization","Local tumor control","Tumor recurrence","Progression-free survival","Hepatocellular carcinoma","Liver metastases","Renal cell carcinoma","Lung tumors","Musculoskeletal tumors","Registry","Multicenter","NOT_YET_RECRUITING","2026-06-03",{"date":166,"type":44},"2026-06-09",{"date":168,"type":21},"2026-07-01",{"date":170,"type":21},"2030-12-31",{"name":172,"class":114},"Mark C Burgmans, MD PhD",3,{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":87,"phases":183,"briefSummary":186,"conditions":187,"keywords":200,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":212},"100610425","phase-1-symbiotic-gu-08-a-study-to-learn-about-the-medicine-called-pf-08634404-dosed-alone-and-in-combination-with-other-anticancer-therapies-in-adults-with-locally-advanced-or-metastatic-renal-cell-cancer-100610425","NCT07227415","Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer","AN INTERVENTIONAL PHASE 1B\u002F2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA","Inclusion Criteria:\n\n* 18 years of age or older at screening\n* Locally advanced (not amenable to curative surgery or radiation therapy) or metastatic RCC with diagnosis confirmed by histology\u002Fcytology\n* At least one measurable (as defined by the investigator) and untreated lesion\n* Adequate hematologic, hepatic, cardiac and renal function\n* No prior systemic therapy for RCC (immunotherapy after surgery is allowed if received \\>12 months prior)\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n* All International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) based risk categories\n\nExclusion Criteria:\n\nParticipants may be excluded if they meet any of the following:\n\n* Known active brain lesions including leptomeningeal metastasis, brainstem, meningeal or spinal cord metastases or compression.\n* Clinically significant risk of haemorrhage or fistula\n* History of another malignancy within 3 years\n* History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.\n* active autoimmune diseases requiring systemic treatment within the past 2 years\n* uncontrolled cardiac and other comorbidities within 6 months prior to the first dose\n* Major surgery or severe trauma within 4 weeks before the first dose, or planned major surgery during the study\n* History of severe bleeding tendency or coagulation dysfunction\n* History of oesophageal varices, severe ulcers, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess or acute gastrointestinal bleeding within 6 months prior to the first dose\n* Acute, chronic or symptomatic infections\n* Participants with history of immunodeficiency",{"count":182,"type":21},224,[184,185],"PHASE1","PHASE2","This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the study medicine, when given alone or with other anticancer medicines, and how this type of cancer responds to them.\n\nTo join the study, participants must be adults; with locally advanced or metastatic RCC; who have not received treatment for their advanced kidney cancer.\n\nParticipants will receive study medicine either alone or with other anticancer medicines. The medicine will be given through intravenous (IV) infusions, which means it will be injected directly into a vein. All treatments will take place at clinical study sites, where trained medical staff will take care of participants during and after each visit.",[188,189,29,190,191,192,193,194,195,196,197,198,199],"Carcinoma, Renal Cell","Advanced Renal Cell Carcinoma","Renal Neoplasm","Clear Cell Renal Cell Carcinoma","Metastatic Renal Cell Carcinoma","Clear-cell Metastatic Renal Cell Carcinoma","Carcinoma, Renal Cell Metastasis","Advanced or Metastatic Renal Cell Carcinoma","Carcinoma, Renal Cell, Advanced","Metastatic Renal Cell Cancer","Metastatic Renal Cell Carcinoma ( mRCC)","Metastatic\u002FAdvanced Renal Cell Carcinoma",[158,201,202],"renal cancer","renal neoplasm",{"date":204,"type":44},"2026-06-04",{"date":206,"type":44},"2026-02-10",{"date":208,"type":21},"2028-11-01",{"name":210,"class":211},"Pfizer","INDUSTRY",109,{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":163,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":76},"100640307","a-study-comparing-single-port-and-multi-port-robot-assisted-surgery-in-patients-with-prostate-or-kidney-renal-cancer-100640307","NCT07610083","A Study Comparing Single-Port and Multi-Port Robot-Assisted Surgery in Patients With Prostate or Kidney (Renal) Cancer","Single-port vs. Multi-port Robot-assisted Surgery for Prostate or Renal Cancer","Inclusion Criteria:\n\n* The participant provides written informed consent\n* Male or female participants who are at least 18 years of age on the day of signing informed consent\n* Men with a diagnosis of prostate or renal cancer and women with a diagnosis of renal cancer\n* Pre-operative imaging performed for staging purposes (i.e. CT scan, PSMA PET) showing no suspicious evidence of distant metastases in prostate or renal cancer patients\n* Suitable for RARP or RAPN.\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years\n* Mental or physical disability that may prevent the patient from satisfying the requirements of the protocol\n* Inability to read and sign the informed consent\n* No available pre-operative staging\n* Contraindication to surgery\n* Presence of distant metastases (M1)",{"count":221,"type":21},376,"This is a prospective single-center observational study comparing single-port (SP) and multi-port (MP) robot-assisted surgery in adult patients undergoing robot-assisted radical prostatectomy (RARP) or robot-assisted partial nephrectomy (RAPN) for prostate or kidney cancer.\n\nConsecutive eligible patients will be managed according to routine clinical practice and assigned to SP or MP surgery based on predefined clinical and anatomical criteria, surgeon assessment, patient and tumor characteristics, platform availability, and surgical expertise. No randomization will be performed.\n\nThe study aims to compare perioperative outcomes between the two surgical approaches, with length of hospital stay (LOS) as the primary endpoint. Secondary endpoints include intraoperative outcomes (operative time, estimated blood loss, and intraoperative complications), postoperative recovery, pain, postoperative complications, readmission rates, positive surgical margins, and hospital costs.\n\nFunctional and patient-reported outcomes will also be evaluated, including urinary continence, sexual function, health-related quality of life, renal function after partial nephrectomy, decision regret, and cosmetic satisfaction.",[224,29],"Prostate Cancer","2026-05-20",{"date":227,"type":44},"2026-05-27",{"date":229,"type":21},"2026-06",{"date":231,"type":21},"2030-06",{"name":233,"class":114},"IRCCS San Raffaele",{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":87,"phases":243,"briefSummary":244,"conditions":245,"keywords":252,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":76},"100456579","video-education-with-result-dependent-disclosure-100456579","NCT05225428","Video Education With Result Dependent dIsclosure","VERDI","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Current or prior diagnosis of breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, colorectal cancer, renal cancer, melanoma, or sarcoma\n* Ability to understand spoken or written English or Spanish in a healthcare context\n* Ability to understand and the willingness to sign a written informed consent document\n* Black or Latinx (qualitative assessment study only)\n\nExclusion Criteria:\n\n* Prior cancer genetic testing\n* Prior germline genetic testing\n* Active hematologic malignancy (e.g. chronic lymphocytic leukemia)\n* Currently pregnant\n* Currently incarcerated",{"count":242,"type":21},1020,[89],"The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic testing (pretest) education alternative in clinical practice, to better serve a more diverse patient population at risk for hereditary cancers.",[246,247,248,249,224,250,29,251,25],"Genetic Testing","Breast Cancer","Ovarian Cancer","Pancreatic Cancer","Colorectal Cancer","Melanoma",[246,247,248,249,224,250,29,251,25],{"date":254,"type":44},"2026-05-22",{"date":256,"type":44},"2022-08-04",{"date":258,"type":21},"2026-10-01",{"name":260,"class":114},"Dana-Farber Cancer Institute",{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":268,"enrollmentInfo":269,"targetDuration":4,"studyType":87,"phases":271,"briefSummary":272,"conditions":273,"keywords":280,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":76},"100581617","phase-2-cd70-targeted-immunopet-imaging-of-malignant-cancers-100581617","NCT06852638","CD70-targeted immunoPET Imaging of Malignant Cancers","CD70-targeted PET\u002F CT in the Diagnosis of Malignant Cancers","Inclusion Criteria:\n\n* Aged 18-80 year-old and of either sex；\n* Histologically confirmed diagnosis of renal cancer (especially ccRCC)\u002Flymphoma\u002FNPC or suspected renal cancer\u002Flymphoma\u002FNPC by diagnostic imaging;\n* Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol.\n\nExclusion Criteria:\n\n* Pregnancy；\n* Severe hepatic and renal insufficiency;\n* Allergic to single-domain antibody radiopharmaceuticals.","80 Years",{"count":270,"type":21},300,[185],"This study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography\u002Fcomputed tomography (immunoPET\u002FCT) imaging for diagnosing human malignancies, including renal cell carcinoma (particularly clear cell renal cell carcinoma), lymphoma, and nasopharyngeal carcinoma (NPC), among others.",[29,274,275,276,277,278,279],"Renal Clear Cell Carcinoma","Lymphoma","Lymphoma, Large B-Cell, Diffuse","Follicular Lymphoma","Mantle Cell Lymphoma","Nasopharyngeal Carcinoma",[281,282,29,275,279],"The cluster of differentiation (CD70)","ImmunoPET","2026-05-07",{"date":285,"type":44},"2026-05-12",{"date":287,"type":44},"2024-12-23",{"date":289,"type":21},"2026-12-23",{"name":291,"class":114},"RenJi Hospital",{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":87,"phases":301,"briefSummary":302,"conditions":303,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":325},"100534466","phase-1-dose-escalation-and-dose-expansion-study-of-mdx2001-in-patients-with-advanced-solid-tumors-100534466","NCT06239194","Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors","A Phase 1\u002F2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n* Patients must be ≥ 18 years of age\n* Histologically or cytologically confirmed diagnosis of metastatic solid tumors\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* All patients should have at least 1 measurable disease per RECIST v1.1. An irradiated lesion can be considered measurable only if progression has been demonstrated on the irradiated lesion.\n* All contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n* Adequate hematologic, hepatic and renal function\n* Capable of giving signed informed consent\n\nExclusion Criteria:\n\n* Any clinically significant cardiac disease\n* Unresolved toxicities from previous anticancer therapy\n* Prior solid organ or hematologic transplant\n* Known untreated, active, or uncontrolled brain metastases\n* Known positivity with human immunodeficiency virus (HIV), known active hepatitis B or C, or uncontrolled chronic or ongoing infectiion requiring intravenous treatment.\n* Receipt of a live-virus vaccination within 28 days of planned treatment start\n* Patient not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions.\n* Participation in a concurrent clinical study in the treatment period.\n* Known hypersensitivity to MDX2001 or any of its ingredients\n* Supplemental oxygen use for activities of daily living\n\nThe above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.",{"count":300,"type":21},285,[184,185],"This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.",[304,247,305,306,307,308,309,310,311,312,313,249,224,314,29,315],"Biliary Tract Cancer","Cervical Cancer","Colon Cancer","Endometrial Cancer","Esophageal Cancer","Gastric Cancer","GastroEsophageal Cancer","Head and Neck Cancer","Hepatocellular Cancer","Non-small Cell Lung Cancer","Rectal Cancer","Thyroid Cancer","2026-05-03",{"date":318,"type":44},"2026-05-06",{"date":320,"type":44},"2024-06-12",{"date":322,"type":21},"2029-02",{"name":324,"class":211},"ModeX Therapeutics, An OPKO Health Company",6,{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":332,"eligibilityCriteria":333,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":87,"phases":336,"briefSummary":337,"conditions":338,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":173},"100513747","phase-2-neoadjuvant-pembrolizumab-and-axitinib-in-renal-cell-carcinoma-with-inferior-vena-cava-tumor-thrombus-100513747","NCT05969496","Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus","Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Associated Inferior Vena Cava Tumor Thrombus (NEOPAX)","NEOPAX","Inclusion Criteria:\n\n* Provision to sign and date the consent form.\n* Stated willingness to comply with all study procedures and be available for the duration of the study.\n* Participant self-identified gender ages \\>\u002F= 18 years old is acceptable and appropriate if they meet other inclusion criteria.\n* Histologically proven clear cell component RCC.\n* An upfront candidate for definitive surgery per treating Urologist.\n* Suitable for and willing to undergo nephrectomy (either cytoreductive or with curative intent) per treating urologist.\n* T Stage of any of the following: cT3b, cT3c, cT4\n* N stage of any of the following: cN0 or cN1\n* M stage of any of the following: cM0 or cM1\n* ECOG performance status 0 - 2.\n* Urinalysis \\\u003C2+ protein. If dipstick is ≥2+ then a 24-hour urine collection should be performed, and the patient may enter the trial if urinary protein is \\\u003C2g per 24 hours.\n* All participants who have reproductive potential must have a negative serum or urine pregnancy test within a maximum of 14 days prior to starting trial treatment.\n\nReproductive potential is defined as the following:\n\n* Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n  * Women \\\u003C50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy)\n  * Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \\>1 year ago, had chemotherapy-induced menopause with last menses \\>1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy\n  * For males with reproductive potential, use effective birth control during treatment with Axitinib and Pembrolizumab is recommended.\n\nExclusion Criteria:\n\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to enrollment.\n* Has had major surgery within 4 weeks or received radiation therapy within 1 week prior to enrollment to the study.\n* Has had prior treatment with any anti-programmed cell death (anti-PD-1) or programmed cell death ligand 1 (PD-L1), or an antibody targeting any other immune-regulatory receptors or mechanisms.\n* Has received prior systemic anti-cancer therapy for RCC with vascular endothelial growth factor (VEGF)\u002FVEGF receptors (VEGFR).\n* Has a history of severe hypersensitivity reaction (e.g., generalized rash\u002Ferythema, hypotension, bronchospasm, angioedema, or anaphylaxis) to Axitinib.\n* Has a diagnosis of immunodeficiency OR is receiving a systemic steroid therapy greater than Prednisone 10 mg daily or a steroid equivalent, or any other form of immunosuppressive therapy within 7 days prior to enrollment to the study except in the case of central nervous system (CNS) metastases.\n* Has an active autoimmune disease requiring systemic treatment within the past 2 years OR a documented history of clinically severe autoimmune disease. Note: Participants with vitiligo, Sjogren's syndrome, Type 1 diabetes, resolved childhood asthma\u002Fatopy, hypothyroidism or adrenal or pituitary insufficiency who are stable on hormone replacement are not excluded.\n* Has a known additional malignancy that has progressed or has required active treatment in the last 3 years. Note: Basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ such as breast cancer in situ, thyroid cancer (papillary, hurthle cell or follicular), or localized prostate cancer are acceptable if they have undergone potentially curative therapy.\n* Has known active CNS metastases and\u002For carcinomatous meningitis.\n* Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.\n* ALT or AST above 3 times the upper limit of normal\n* Has received a live virus vaccine within 30 days of enrollment to the study.\n* Active GI bleeding, as evidenced by hematemesis, hematochezia, or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy.\n* Intraluminal metastatic lesion with suspected bleeding, inflammatory bowel disease, ulcerative colitis or other GI condition associated with increased risk of perforation.\n* Has QT interval corrected for heart rate (QTc) ≥480 msec.\n* Has a history of any of the following cardiovascular conditions within 12 months of enrollment to the study:\n\n  * Myocardial infarction\n  * Unstable angina pectoris\n  * Cardiac angioplasty or stenting\n  * Coronary\u002Fperipheral artery bypass graft\n  * Class III or IV congestive heart failure per New York Heart Association\n  * Cerebrovascular accident or transient ischemic attack\n* Has poorly controlled hypertension defined as systolic blood pressure (SBP) ≥150 mm Hg and\u002For diastolic blood pressure (DBP) ≥90 mm Hg on 3 or more dose optimized anti- hypertensive medication.\n* Has evidence of inadequate wound healing per treating physician discretion.\n* Has active bleeding disorder or other history of significant bleeding episodes within 30 days of enrollment to the study.\n* Has current use (within 7 days of enrollment) or anticipated need for treatment with drugs or foods that are known to be strong cytochrome P450 (CYP3A4\u002F5) inhibitors.\n* Has current use (within 7 days of enrollment) or anticipated need for treatment with drugs that are known strong CYP3A4\u002F5 inducers, including but not limited to carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, and St. John's wort; or drugs that are known with proarrhythmic potential.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study by subject self-report.\n* Has had a prior solid organ transplant.\n* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study drug.",{"count":335,"type":21},17,[185],"The primary objective of this study is to evaluate whether the combination of Pembrolizumab and Axitinib given in the neoadjuvant setting can change the Inferior Vena Cava Tumor Thrombus burden. A decrease in the size of the tumor thrombus can potentially lead to decrease in surgical complications, improve patient related health outcomes, and improve long term outcomes such as progression free survival and overall survival.",[29,39,339,340],"Renal Cell Carcinoma","Inferior Vena Cava Thrombosis","2026-04-06",{"date":343,"type":44},"2026-04-13",{"date":345,"type":44},"2023-12-04",{"date":347,"type":21},"2029-11",{"name":349,"class":114},"University of Colorado, Denver",{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":354,"acronym":4,"eligibilityCriteria":355,"healthyVolunteers":16,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":356,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":358,"conditions":359,"keywords":360,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":375},"100215908","kidney-cancer-dna-registry-100215908","NCT02087852","Kidney Cancer DNA Registry","Inclusion Criteria:\n\nKidney Cancer Case Cohort:\n\n* Must be ≥ 18 years of age AND\n* Must be an English-speaker AND\n* Must have a diagnosis or suspicion of kidney cancer\n\nFamily Member Cohort:\n\n* Must be ≥ 18 years of age AND\n* Must be an English-speaker AND\n* Must be a blood relative of the proband. Family members of probands including mother, father, sisters, brothers, half-sisters, half-brothers, daughters, sons, grandmothers, grandfathers, as well as aunts and uncles are eligible. These individuals need not have kidney cancer, as they will be used for segregation analysis of suspected variants found in the proband; requesting DNA from relatives is required.\n\nControl Cohort:\n\n* Must be ≥ 18 years of age AND\n* Must be an English-speaker AND\n* Must not have a personal history of cancer, with the exception of nonmelanoma skin cancer, AND\n* Must not be a blood relative of any cases or controls enrolled in this study\n\nExclusion Criteria:\n\n* Patients who, in the opinion of the primary MSKCC clinician or the investigator, have a condition that precludes their ability to provide an informed consent",{"count":357,"type":21},750,"This registry will help us develop better methods of:\n\n* Preventing these cancers\n* Diagnosing these cancers\n* Treating these cancers",[29],[361,362,363,364,365,366],"Questionnaire","DNA","saliva","kidney cancer","13-218","high risk",{"date":368,"type":44},"2026-04-09",{"date":370,"type":4},"2014-03",{"date":372,"type":21},"2027-03",{"name":374,"class":114},"Memorial Sloan Kettering Cancer Center",7,{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":87,"phases":385,"briefSummary":386,"conditions":387,"keywords":392,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":76},"100507526","phase-1-64cu-grip-b-in-patients-with-advanced-malignancies-100507526","NCT05888532","64Cu-GRIP B in Patients With Advanced Malignancies","A First-in-Human, Phase I\u002FII PET Imaging Study of 64Cu-GRIP B, a Radiotracer Targeting Granzyme B, in Patients With Advanced Malignancies","Inclusion Criteria:\n\n1. Disease characteristics by cohort, as defined by:\n\n   Cohort A:\n   * Histologically-confirmed metastatic solid tumor malignancy (3 Male, 3 Female)\n   * Locally advanced or metastatic disease on conventional imaging\n\n   Cohort B:\n   * Histologically-confirmed metastatic renal cell carcinoma (any histologic sub-type) or urothelial carcinoma\n   * Locally advanced or metastatic disease on conventional imaging\n\n   Cohort C:\n   * Histologically-confirmed prostate adenocarcinoma\n   * Metastatic castration resistant prostate cancer by Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria\n2. Planned treatment with immune checkpoint inhibitor (Cohorts B and C only)\n3. Willing to undergo paired tumor biopsies and has safely accessible bone or soft tissue lesion (Cohorts B and C only)\n4. The subject is able and willing to comply with study procedures and provide signed and dated informed consent.\n5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n6. Age 18 years or older at the time of study entry.\n7. Adequate organ function, as defined by:\n\n   * Serum creatinine \\\u003C= 1.5 x upper limit of normal (ULN) or estimated creatinine clearance \\> 60 mL\u002Fmin\n   * Total bilirubin \\\u003C= 1.5 x ULN (\\\u003C 3 x ULN in patients with documented or suspected Gilbert's).\n   * Hemoglobin \\>= 8.0 g\u002FdL\n   * Platelet count \\>= 75,000\u002Fmicroliter\n   * Absolute neutrophil count ≥ 1000\u002Fmicroliter\n8. Patients must not be pregnant or breast feeding. Women of childbearing potential are required to obtain a negative pregnancy test within 14 days of PET Imaging scan. Effective contraception (men and women) must be used in subjects of child-bearing potential.\n\nExclusion Criteria:\n\n1. Patients who because of age, general medical or psychiatric condition, or physiologic status cannot give valid informed consent.\n2. Any condition that, in the opinion of the Principal Investigator, would impair the patient's ability to comply with study procedures.\n3. Is currently pregnant or breastfeeding.",{"count":384,"type":21},91,[184,185],"This phase I\u002FII clinical trial evaluates if using a radiotracer targeting granzyme B, 64-copper granzyme targeting restricted interaction peptide specific to family member B (64 Cu-GRIP B) with positron emission tomography (PET) imaging can be safe and useful for detecting granzyme B (GrB) in patients with advanced cancers that has spread to nearby tissue or lymph nodes (advanced). Granzyme B (GrB) is a biomarker produced by immune cells in response to immunotherapy, which may highlight tumors that are more likely to respond to treatment. The study population is focused on genitourinary (GU) malignancies, including renal cell and urothelial cancer, two tumor types with high mutational burden and tumor infiltrating lymphocytes compared to other tumor types, and have a predictable response rate at the population level to immune checkpoint inhibitors. The information gained from this trial may allow researchers to develop future trials where 64Cu-GRIP B PET may serve as a biomarker to monitor early response to immunomodulatory therapies which are used to stimulate or suppress the immune system and may help the body fight cancer.",[224,29,388,389,390,391],"Urethral Cancer","Advanced Solid Tumor","Metastatic Castration-resistant Prostate Cancer","Solid Tumor, Adult",[393,394,395],"Imaging Study","Radiotracer","Granzyme B","2026-03-13",{"date":398,"type":44},"2026-03-17",{"date":400,"type":44},"2023-05-25",{"date":402,"type":21},"2027-01-31",{"name":404,"class":114},"Rahul Aggarwal",{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":412,"enrollmentInfo":413,"targetDuration":4,"studyType":87,"phases":414,"briefSummary":415,"conditions":416,"keywords":419,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":431},"100438269","68ga-psma-pet-in-the-renal-cell-carcinoma-100438269","NCT04987086","68Ga-PSMA PET in the Renal Cell Carcinoma","A Prospective, Multicenter Study of Diagnostic Efficiency of 68Ga-PSMA PET in the Patients With Locally Advanced and Advanced Renal Cell Carcinoma","Inclusion Criteria:\n\n* 2017 AJCC renal cell carcinoma TNM stage III, IV lesions;\n* In contrast-enhanced CT staging, suspicious metastases were found;\n* There were no known peripheral or central venous problems;\n* 68Ga PSMA PET \u002F CT imaging can be performed within 6 weeks after the diagnosis of renal cell carcinoma;\n* Signed the informed consent form of voluntary participation in clinical trials.\n\nExclusion Criteria:\n\n* Age ≤ 18 years old;\n* Can't stand lying flat in PET \u002F CT examination;\n* There are contraindications for 68Ga PSMA ligands;\n* In the past two years, there was a history of other malignant tumors, or according to the doctor's research judgment, complications may occur and affect the normal operation of the test;\n* Renal function is impaired or hemodialysis is in progress.","90 Years",{"count":270,"type":21},[89],"The primary research purpose is to evaluate the diagnostic efficacy of 68Ga-PSMA PET in metastatic lesions of locally advanced and advanced renal cell carcinoma, and to compare with that of enhanced CT. The second purpose is to evaluate whether 68Ga-PSMA PET can change the treatment decision of patients with locally advanced and advanced renal cell carcinoma",[29,417,418],"Metastases","PSMA PET",[420,418,421],"advnaced renal cancer","metastases","2026-03-08",{"date":424,"type":44},"2026-03-11",{"date":426,"type":44},"2021-06-01",{"date":428,"type":21},"2027-12-01",{"name":430,"class":114},"Xijing Hospital",9,{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":438,"eligibilityCriteria":439,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":441,"conditions":442,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":76},"100599749","occupational-situation-and-return-to-work-of-urological-patients-100599749","NCT07088536","Occupational Situation and Return to Work of Urological Patients","Occupational Situation of Patients With Urological Diseases and Return to Work in Patients Undergoing Major Uro-Oncological Operations and Procedures for Urinary Tract Stones","OCCURORTW","Inclusion Criteria:\n\n1. Adult patients (≥18 years) admitted to the Department of Urology and Oncological Urology, University Hospital in Kraków, during the 6-month study period.\n2. For the prospective follow-up cohort:\n\n   1. Occupationally active (employed) at baseline.\n   2. Undergoing major uro-oncological surgery (e.g., radical cystectomy, radical prostatectomy, nephrectomy) or a procedure for urinary tract stones (e.g., ureterorenoscopy, percutaneous nephrolithotripsy).\n3. Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n1. Patients unwilling or unable to provide informed consent.\n2. Patients who are unemployed or retired at baseline (excluded from the prospective follow-up cohort but included in the baseline cross-sectional survey).\n3. Patients not undergoing major uro-oncological surgery or urinary tract stone procedures (for the prospective follow-up cohort).",{"count":124,"type":21},"This study will examine the work status of all adult patients admitted over a 6-month period to the University Hospital in Kraków, Poland, for treatment of urological diseases. All admitted patients will be surveyed about their job situation. Patients who are occupationally active and undergoing major oncological surgeries (such as radical cystectomy, prostatectomy, or nephrectomy) or procedures for urinary tract stones will also complete a quality-of-life questionnaire and be followed up by phone at 3 and 6 months. The goal is to learn how treatment affects patients' ability to return to work and their well-being, to help guide support and rehabilitation strategies.",[65,224,29,443],"Urinary Stones","2026-03-02",{"date":446,"type":44},"2026-03-03",{"date":448,"type":44},"2025-07-21",{"date":450,"type":21},"2027-04",{"name":452,"class":114},"Jagiellonian University",{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":87,"phases":461,"briefSummary":462,"conditions":463,"keywords":468,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":489},"100506384","phase-1-a-phase-1-clinical-study-of-nxp900-in-subjects-with-advanced-cancers-100506384","NCT05873686","A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers","Part A\n\nInclusion Criteria:\n\n1. Provide written informed consent.\n2. 18 years old or older.\n3. Advanced, metastatic, and\u002For progressive solid tumors for whom there is no authorized or effective therapy available, or for whom such therapies are considered inappropriate by the Investigator.\n4. Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n\nExclusion Criteria:\n\n1. Subjects with known human epidermal growth factor receptor 2 (HER2+) overexpressing malignancies.\n2. Radiotherapy (except for palliative reasons), endocrine therapy, chemotherapy, or investigational agent within 28 days, (42 days for nitrosoureas, mitomycin-C) of first dose of NXP900. Subjects can continue to receive bisphosphonates due to metastatic bone disease or GnRH agonists if they have prostate cancer.\n3. Ongoing toxic manifestations of previous treatments \\> Grade 2 with the exception of alopecia and neuropathy.\n4. Subjects with treated brain metastases with evidence of progression within 28 days after central nervous system (CNS)-directed treatment, as ascertained by clinical examination and brain imaging (magnetic resonance imaging \\[MRI\\] or computed tomography \\[CT\\] scan) during the Screening period.\n5. Female subjects who can become pregnant (or are already pregnant or lactating), unless they have a negative serum pregnancy test before enrollment and agree to use at least one highly effective form of contraception .\n6. Male subjects with partners of childbearing potential, unless they agree to take measures not to father children by using a barrier method of contraception (condom plus spermicide).\n7. Major surgery from which the subject has not yet recovered.\n\nPart B:\n\nInclusion Criteria:\n\n1. Provide written informed consent.\n2. 18 years old or older.\n3. Advanced, metastatic, and\u002For progressive solid tumors with pathogenic molecular alterations:\n\n   1. Non-small cell lung cancer (adenocarcinoma); YES1, TYMS amplification or FAT1 pathogenic mutation\n   2. Non-small cell lung cancer (squamous cell carcinoma); YES1, TYMS amplification or FAT1 pathogenic mutation\n   3. Renal cancer; NF2 pathogenic mutation\n   4. Mesothelioma; NF2 pathogenic mutation\n   5. Other solid tumors with a NF2, FAT1 or LATS1 pathogenic gene mutation or TYMS, YAP1, YES1, TAZ1 gene amplification\n4. Must have received 1-3 prior therapies appropriate for their tumor type and stage of disease\n5. Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n\nExclusion Criteria:\n\n1. Subjects with the following combination of cancer type and pathogenic molecular alterations are excluded:\n\n   1. Subjects with colorectal cancer, glioma, melanoma, or anaplastic thyroid conditions with BRAF mutations.\n   2. Subjects with NSCLC with BRAF, EGFR or HER2 alterations.\n   3. Subjects with breast cancer, gastric cancer, esophageal junction adenocarcinoma or biliary cancer with HER2 alterations,\n2. Subjects with anal, penile, cervical or head and neck cancers with a prior history of human papilloma virus (HPV) infection.\n3. Radiotherapy (except for palliative reasons), endocrine therapy, chemotherapy, or investigational agent within 28 days (42 days for nitrosoureas, mitomycin-C) prior to first dose of NXP900. Subjects can continue to receive bisphosphonates due to metastatic bone disease or GnRH agonists if they have prostate cancer.\n4. Ongoing toxic manifestations of previous treatments \\> Grade 2 with the exception of alopecia and neuropathy.\n5. Female subjects who can become pregnant (or are already pregnant or lactating), unless they have a negative serum pregnancy test before enrollment and agree to use at least one highly effective form of contraception .\n6. Male subjects with partners of childbearing potential, unless they agree to take measures not to father children by using a barrier method of contraception (condom plus spermicide).\n7. Major surgery from which the subject has not yet recovered.",{"count":460,"type":21},140,[184],"This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterations) targets of NXP900.",[389,464,29,465,466,467],"NSCLC (Non-small Cell Lung Cancer)","Mesothelioma","Non-Small Cell Squamous Lung Cancer","Non-small Cell Lung Adenocarcinoma",[38,469,470,471,472,473,474,475,476,477,478,479,480],"Carcinoma","Neoplasms","Adenocarcinoma","YES1","YAP1","TAZ1","NF2","FAT1","LATS1","TYMS","gene amplification","gene mutation","2026-02-27",{"date":446,"type":44},{"date":484,"type":44},"2023-10-26",{"date":486,"type":21},"2027-07",{"name":488,"class":211},"Nuvectis Pharma, Inc.",12,{"id":491,"slug":492,"hasResults":12,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":496,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":498,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":500,"conditions":501,"keywords":505,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":76},"100623315","a-study-of-ward-admissions-for-haematuria-100623315","NCT07395037","A Study of Ward Admissions for Haematuria","Ward AdmiSsion of Haematuria: an Observational mUlticentre sTudy","WASHOUT","Inclusion Criteria:\n\n* Patients are included if they are over 16 years of age or older and admitted to a participating urological secondary care centre\n* admitted as an emergency with haematuria as the primary or secondary diagnosis under the primary or joint care of urology\n\nExclusion Criteria:\n\n* any patients under 16 years of age\n* patients with catheter-related urethral trauma (defined as haemturia immediately after insertion of a urethral catheter that was documented as traumatic by the clinician, with no previous history of haemturia prior to catheter insertion)\n* patients that are in hospital less than 24 hours.",{"count":499,"type":21},1050,"This multicenter, prospective observational study will evaluate national and international practice variations (if present) in the emergency management of patients admitted to hospital with haematuria, inform a consensus guideline for best practice and provide evidence to design an implementation study to optimise haematuria management pathway.",[502,503,504,65,29,92],"Urologic Diseases","Hematuria","Hematuria; Benign",[506,507,508,509],"catheter","haematuria","hematuria","irrigation","2026-02-03",{"date":512,"type":44},"2026-02-09",{"date":514,"type":44},"2024-01-01",{"date":516,"type":21},"2026-04-30",{"name":518,"class":114},"British Urology Researchers in Surgical Training",{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":525,"eligibilityCriteria":526,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":527,"targetDuration":4,"studyType":87,"phases":529,"briefSummary":531,"conditions":532,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":547,"locationsCount":173},"100542961","phase-3-spinal-morphine-or-intravenous-lidocaine-in-robot-assisted-upper-urologic-surgery-100542961","NCT06349668","Spinal Morphine or Intravenous Lidocaine in Robot-assisted Upper Urologic Surgery","SMILe: Spinal Morphine or Intravenous Lidocaine in Robot-assisted Upper Urologic Surgery","SMILe","Inclusion Criteria:\n\n* The patient is scheduled for elective robotic-assisted upper urinary tract surgery at one of the participating hospitals\n* The patient gives oral and written informed consent after having received oral and writen information about the study\n\nExclusion Criteria:\n\n* The patient has a ASA-class of IV or above\n* The patient is a minor or declared incompetent, has severe psychiatric disease or is expected not to be able to understand the study information due to severe restrictions in vision, hearing, cognition, reading or Swedish language abilities\n* The patient is a female who is pregnant or breastfeeding\n* The patient is a pre-menopausal female who has not undergone sterilisation, hysterectomy, bilateral salpingectomy and\u002For bilateral oophorectomy, and is not using highly-effective contraception with low user-dependency and cannot provide a negative pregnancy test\n* The patient is scheduled for emergency surgery\n* Research staff not available\n* Scheduled significant simultaneous surgery on another organ\n* The anesthesiologist in charge has planned spinal or epidural analgesia\n* The patient has clear contraindications to spinal analgesia, e.g. severe coagulopathy, severe aortic stenosis, previous back surgery with rods, or spinal analgesia can be expected to be technically challenging (severe obesity, severe scoliosis)\n* The patient has clear contraindications to lidocaine infusion, e.g. proven allergy to local anesthetics, myasthenia gravis, renail failure (eGFR \\\u003C 30), hepatic failure caused by acute hepatitis or cirrhosis (Child-Pugh B or higher, severe cardiac arrythmias or insuffiency (NYHA IIIb or higher)\n* The patient has previously participated in the trial",{"count":528,"type":21},220,[530],"PHASE3","The goal of this clinical trial is to learn whether the addition of spinal analgesia leads to superior recovery in patients undergoing robotic-assisted laparoscopic upper urinary tract surgery under general anesthesia. The main questions it aims to answer are:\n\n* Is the decrease in wellbeing as quantified by the patient-centered outcome scale \"Quality of Recovery 15\" (QoR-15), from baseline to the first day after surgery (POD 1), at least 8.0 points less in patients receiving spinal analgesia in addition to general anesthesia?\n* Does spinal analgesia result in improved recovery as quantified by QoR-15 at POD 7, the incidence of postoperative pain at rest and at mobilization, nausea and vomiting, the need for opioid analgesics, time out-of-bed, length of stay and the incidence of complications?\n* Does spinal analgesia increase workload in the OR, as quantified by time from arrival in the OR to start of surgery?\n* Does spinal analgesia result in an increased incidence of hypotension and cardiac dysfunction during surgery, as well as an increased incidence of pruritus after surgery?\n\nParticipants will be randomized to receive either spinal analgesia with bupivacaine and morphine preoperatively or an intravenous infusion with lidocaine intraoperatively.\n\nQoR-15 and other markers of recovery will be registered using structured interviews preoperatively, at POD1 and POD7. In addition, patients will record pain at rest and at mobilization three times daily in a diary.\n\nIn a subgroup of patients advanced hemodynamic parameters will be recorded using pulse-contour analysis before, during and after surgery. Blood samples will also be collected in these patients at fixed intervals and analyzed for amongst others inflammation and cardiac dysfunction.",[533,534,535,536,537,538,539,29],"Other Specified Disorders of Kidney and Ureter","Benign Neoplasm of Ureter","Calculus of Kidney and Ureter","Ureter Cancer","Ureteric Reflux","Congenital Ureteric Anomaly","Benign Renal Neoplasm","2026-02-02",{"date":542,"type":44},"2026-02-05",{"date":544,"type":44},"2024-04-09",{"date":546,"type":21},"2027-12-31",{"name":548,"class":114},"Hans Bahlmann",{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":553,"acronym":4,"eligibilityCriteria":554,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":555,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":557,"conditions":558,"keywords":561,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":573,"locationsCount":325},"100101408","ascertainment-of-families-for-genetic-studies-of-familial-lymphoproliferative-disorders-100101408","NCT00582621","Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders","Inclusion Criteria:\n\n* Individuals with a personal and\u002For family history of lymphoma or lymphoproliferative disease B-cell malignancies, or multiple myeloma referred for study participation, or MSK patients referred from to the MSKCC outpatient clinics of the Lymphoma, Multiple Myeloma, or Leukemia Services in the Department of Medicine in consultation for treatment who are found on routine history or through a Family History Questionnaire (FHQ) (Appendix A). Individuals who have relatives or members of successive generations of the family affected with Hodgkin's disease, non-Hodgkin's lymphoma, lymphoid leukemia, multiple myeloma other lymphoproliferative disease prostate or pancreatic cancers, or other conditions suggesting hereditary cancer at the discretion of the MSKCC Principal Investigator. Patients with lymphoma, associated with colon and renal cancer will be eligible for DNA storage through this protocol. Family members or probands with Hodgkin's disease who are women who received therapeutic irradiation for Hodgkin's disease\" or who developed secondary cancers after Hodgkin's disease are also eligible for participation.\n* The criteria for eligibility are broad because the ascertainment by the computerized FHQ does not allow for resolution of different types of lymphoma or different types of leukemia. Patient recall of this information is also imprecise. More accurate family history information will be obtained upon contact of family members and diagnoses will be verified by obtaining pathologic documentation. The spectrum of familial lymphoproliferative syndromes (LPS) may include all types of lymphoma as well as chronic lymphocytic leukemia. This is an additional reason to have a broad eligibility. Subset analysis will be performed on specific types of lymphoid neoplasms. DNA of patients with a family history of lymphoma who have consented to protocol 93-102 (\"Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers\") will also be eligible for inclusion in this study.\n* Family members of probands including patients, sisters, brothers, halfbrothers and sisters, sons, daughters, grandparents, as well as aunts and uncles are also eligible. An effort will be made to ascertain all living affected and unaffected living relatives in the affected lineage. An emphasis will be on affected sibling pairs and both parents, if alive.\n* As this study involves research that presents no greater than minimal risk to children (see Sec. 46.404 of Federal Regulations part 46), minors are also eligible for participation. The assent of any minor should be obtained before the patient is enrolled into this study, as well as the consent of the legal guardian.\n\nExclusion Criteria:\n\n* N\u002FA",{"count":556,"type":21},500,"The purpose of this study is to better understand the genetic causes of Hodgkin's disease (a kind of lymphoma) and non-Hodgkin's lymphoma, as well as multiple myeloma, leukemia, and related diseases. The doctors have identified the patient because 1) they have had a lymphoproliferative disorder such as lymphoma, leukemia, or multiple myeloma, and have a family member with one of these disorders or 2) they are a member of a family with a lymphoproliferative disorder, including Hodgkin's disease and\u002For, non-Hodgkin's lymphoma or a second cancer after Hodgkin's disease.",[275,559,560,306,29],"Leukemia","Multiple Myeloma",[562,563,564,363,565],"Genetic Studies","00-069","blood","buccal cell","2026-01-21",{"date":568,"type":44},"2026-01-23",{"date":570,"type":4},"2000-07",{"date":572,"type":21},"2026-12",{"name":374,"class":114},{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":578,"acronym":4,"eligibilityCriteria":579,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":580,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":582,"conditions":583,"keywords":584,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":591,"startDateStruct":592,"completionDateStruct":594,"leadSponsor":596,"locationsCount":598},"100615957","prospective-observational-trial-of-image-guided-ablative-stereotactic-body-radiation-therapy-for-primary-kidney-cancer-the-stone-trial-100615957","NCT07299357","Prospective Observational Trial of Image-guided Ablative STereotactic bOdy Radiation Therapy for Primary kidNey Cancer: the STONE Trial","Inclusion Criteria:\n\n* Age ≥ 18 years\n* ECOG performance status 0 - 2\n* Histologically confirmed diagnosis of primary RCC\n* cT1 stage tumor with single lesion with maximum diameter of 7 cm\n* Medically inoperable or at high risk of complication from surgery, or declined surgery\n* Absence of metastatic disease\n* Written informed consent\n\nExclusion Criteria:\n\n* Estimated glomerular filtration rate (eGFR) \\\u003C 30 mls\u002Fmin\n* Previous radiotherapy on the same site\n* Previous systemic therapy for RCC\n* Tumor diameter larger than 7 cm\n* Presence of metastatic disease\n* Life expectancy \\\u003C 3 months",{"count":581,"type":21},53,"The study objective is to evaluate the use of Stereotactic Body Radiotherapy (high dose of radiation in a few fractions) to cure primary renal cancer in those patients that are not indicated to surgery (high risk of complications, refusal of the patient). This therapy is already used in clinical setting for many tumors with good tolerance as it is not invasive, does not require anesthesia and hospitalization making it suitable for elderly people and frail patients. However there are not enough information regarding the use of ablative doses for the cure of renal cancer and for this reason this study aims to support the use of Stereotactic Body Radiotherapy as a standard of care for inoperable primary renal tumor. This is an observational study, so it collects data from clinical pratice only and does not request study specific procedures.",[29],[201,585,586,587,588,589],"stereotactic body radiotherapy","radiotherapy","cancer treatment","renal cancer treatment","surgery","2026-01-19",{"date":566,"type":44},{"date":593,"type":21},"2026-01",{"date":595,"type":21},"2033-12",{"name":597,"class":114},"Istituto Clinico Humanitas",2,{"id":600,"slug":601,"hasResults":12,"nctId":602,"briefTitle":603,"officialTitle":604,"acronym":605,"eligibilityCriteria":606,"healthyVolunteers":16,"sex":17,"minAge":607,"maxAge":4,"enrollmentInfo":608,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":610,"conditions":611,"keywords":616,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":622,"lastUpdatePostDateStruct":623,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":628,"locationsCount":335},"100467447","cfdna-assay-prospective-observational-validation-for-early-cancer-detection-and-minimal-residual-disease-100467447","NCT05366881","cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease","cfDNA Assay Multicenter Prospective Observational Validation for Early Cancer Detection, Minimal Residual Disease, and Relapse","CAMPERR","Case Inclusion Criteria:\n\n* Newly diagnosed (within 120 days) with cancer or a recurrence of a cancer diagnosed \\>5 years ago of one of the following subtypes: Invasive Brain, Breast, Bladder, Cervical, Colorectal, Endometrial, Esophageal, Gastric, Head and Neck, Hepatobiliary, Lung, Ovarian, Pancreatic, Prostate, Renal, Sarcoma, Thyroid; Leukemia, Lymphoma, Multiple Myeloma\n* Able and willing to provide informed consent\n* ≥40 years of age\n\nCase Exclusion Criteria:\n\n* Currently receiving any treatment for cancer\n* Currently taking any demethylating agents\u002FDNA hypomethylating agents\n* Simultaneously diagnosed with two or more invasive cancers\n* Diagnosed with any invasive or non-invasive cancer in addition to the index cancer in the last 5 years\n* Currently diagnosed with any chronic hematopoietic cancer (e.g. chronic CLL) in addition to the index cancer\n* Currently diagnosed with any myelodysplastic syndromes and\u002For precursor hematologic conditions (e.g. MGUS) in addition to the index cancer\n* Women who are known to be pregnant (self-reported)\n\nControl Inclusion Criteria\n\n* Not diagnosed with any cancer in the last 5 years (non-invasive cancer is allowed)\n* Able and willing to provide informed consent\n* ≥40 years of age\n\nControl Exclusion Criteria\n\n* Currently receiving any treatment for cancer\n* Currently taking any demethylating agents\u002FDNA hypomethylating agents\n* Women who are known to be pregnant (self-reported)","40 Years",{"count":609,"type":21},7000,"This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers were selected based on their prevalence and mortality to maximize impact on clinical care.\n\nAdditionally, the ability of the whole-genome methylome enrichment platform to detect minimal residual disease after completion of cancer treatment and to detect relapse prior to clinical presentation will be evaluated in lung cancer. This cancer was selected based on the existing clinical landscape and treatment availability.",[612,247,65,305,250,307,308,613,311,614,559,615,275,560,248,249,224,29,25,315],"Brain Cancer","Stomach Cancer","Hepatobiliary Cancer","Lung Cancer",[617,618,619,620,621],"Multi-cancer early detection","Liquid Biopsy","Methylome","Cancer screening","cell-free DNA","2026-01-16",{"date":624,"type":44},"2026-01-20",{"date":626,"type":44},"2022-05-03",{"date":372,"type":21},{"name":629,"class":211},"Adela, Inc",{"id":631,"slug":632,"hasResults":12,"nctId":633,"briefTitle":634,"officialTitle":635,"acronym":4,"eligibilityCriteria":636,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":637,"targetDuration":4,"studyType":87,"phases":639,"briefSummary":640,"conditions":641,"keywords":4,"overallStatus":163,"whyStopped":4,"lastUpdateSubmitDate":652,"lastUpdatePostDateStruct":653,"startDateStruct":655,"completionDateStruct":657,"leadSponsor":659,"locationsCount":76},"100619216","phase-1-sl-28-for-advanced-solid-tumours-100619216","NCT07341737","SL-28 for Advanced Solid Tumours","A Phase 1\u002F2, Multicentre, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of SL-28 in Patients With Advanced Solid Tumours","Inclusion Criteria:\n\n* Ability to provide written informed consent prior to any study-related procedures and to understand the nature, purpose, and potential risks of the study\n* Adult males and females ≥18 years of age at screening\n* Life expectancy of at least 3 months\n* Histologically or cytologically confirmed unresectable advanced solid tumor (recurrent, metastatic, or locally advanced)\n* Disease refractory to, intolerant of, or refusal of standard therapies, including immunotherapy and molecular\u002Fbiomarker-directed treatments, as determined by the Principal Investigator (PI) or delegate\n* Eligible tumor types include:\n* Head and neck squamous cell carcinoma\n* Thoracic malignancies (small-cell lung cancer, non-small cell lung cancer, esophageal cancer)\n* Gastrointestinal malignancies (gastric, liver, colorectal, pancreatic adenocarcinoma)\n* Genitourinary malignancies (bladder, renal cell, prostate cancer)\n* Gynecologic malignancies (ovarian, endometrial cancer)\n* Breast cancer and melanoma\n* Evaluable disease per RECIST v1.1\n* ECOG performance status 0-1 (or up to 2 at PI discretion)\n* Adequate organ function, defined as:\n* Total bilirubin ≤1.5 × ULN (≤2.0 × ULN for liver metastases or Gilbert's syndrome)\n* AST, ALT, alkaline phosphatase ≤2.5 × ULN (≤5 × ULN if liver metastases, at PI discretion)\n* Creatinine clearance ≥50 mL\u002Fmin (Cockcroft-Gault) or eGFR ≥50 mL\u002Fmin (CKD-EPI)\n* Absolute neutrophil count ≥1,000\u002Fmm³\n* Platelet count ≥100,000\u002Fmm³\n* Hemoglobin ≥90 g\u002FL without transfusion within 2 weeks\n* Prothrombin time and aPTT ≤1.5 × ULN (or stable INR if on anticoagulation)\n\nFemale patients:\n\n-Non-childbearing potential (surgically sterile or postmenopausal), or of childbearing potential with negative pregnancy tests and agreement to effective contraception through 90 days post-dose\n\nMale patients:\n\n* Agreement not to donate sperm for 90 days post-dose\n* Agreement to use adequate contraception as applicable\n* Suitable venous access for blood sampling\n* Willingness and ability to comply with study procedures and protocol requirements\n\nExclusion Criteria:\n\n* Ongoing toxicities ≥ Grade 2 per NCI CTCAE v5.0 (except alopecia, fatigue, sensory neuropathy, or adequately treated endocrine deficiencies)\n* NYHA Class III or IV heart disease, myocardial infarction within 6 months, unstable arrhythmia, or ischemia on ECG\n* QTcF \\>470 ms (females) or \\>450 ms (males)\n* Active, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy\n* Requirement for systemic corticosteroids or other immunosuppressive therapy that cannot be discontinued ≥14 days prior to dosing\n* Prior therapies within restricted timeframes:\n* Immune checkpoint inhibitors or biologics within 28 days\n* Antineoplastic therapies, surgery, radiotherapy, or radiopharmaceuticals within 21 days\n* Unapproved investigational drugs within 5 half-lives\n* Nitrosoureas or mitomycin C within 6 weeks\n* Concurrent malignancy within 5 years, except specified low-risk cancers\n* Pregnancy or breastfeeding\n* Known HIV, hepatitis B (HBsAg positive), or hepatitis C infection\n* Inability or unwillingness to comply with protocol procedures\n* History of anaphylaxis or significant allergy interfering with participation\n* Clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, neurologic, psychiatric, or immunologic disease within 6 months\n* Conditions affecting drug absorption, distribution, metabolism, or excretion\n* Receipt of live vaccines within 28 days prior to screening\n* Participation in another investigational study within 30 days prior to screening",{"count":638,"type":21},60,[184,185],"Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours. The company has recently demonstrated a novel, non-genetic approach to modulate immune cell activity through targeted manipulation of the Universal Receptive System. The purpose of this open label, multi-center clinical trial is to evaluate the anti-tumor activity, safety, and pharmacokinetics, single-agent SL-28 in patients with a diverse array of solid tumors. The study includes an initial Phase 1 dose escalation to determine recommended dose(s) for expansion of SL-28 as a monotherapy and Phase 2 expansion cohorts. The study will enroll patients with advanced solid tumours, including those who failed previous lines of chemo- and immunotherapies.",[642,643,644,645,646,647,308,648,649,650,65,29,224,651,247,248,307,250],"Head & Neck Cancer","Pancreas Carcinoma","Pancreas Cancer, Metastatic","Lung Adenocarcinoma","Lung Cancer (NSCLC)","Lung Cancer (Non-Small Cell)","Stomach (Gastric) Cancer","Liver Cancer","Intestinal Cancer","Melanoma (Skin Cancer)","2026-01-13",{"date":654,"type":44},"2026-01-15",{"date":656,"type":21},"2026-02-01",{"date":658,"type":21},"2027-03-01",{"name":660,"class":211},"Second Life Therapeutics",{"id":662,"slug":663,"hasResults":12,"nctId":664,"briefTitle":665,"officialTitle":665,"acronym":4,"eligibilityCriteria":666,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":667,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":669,"conditions":670,"keywords":671,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":673,"lastUpdatePostDateStruct":674,"startDateStruct":676,"completionDateStruct":678,"leadSponsor":680,"locationsCount":76},"100616293","intra-procedural-spectral-ct-for-image-guided-embolization-and-ablation-in-interventional-oncology-100616293","NCT07303725","Intra-procedural Spectral CT for Image-guided Embolization and Ablation in Interventional Oncology","Inclusion criteria:\n\n1. Age \\> or = 18 years\n2. Tumor in an area without prior surgical or ablative therapy\n3. At least 1 tumor greater than 1.5 cm in greatest diameter\n\nExclusion criteria:\n\n1. Not eligible for indicated procedure.\n2. BMI \\> 35\n3. Prior surgery.",{"count":668,"type":21},30,"This is a pilot study to evaluate the feasibility, image quality, and procedural utility of a novel spectral CT technique using Canon Medical's 4D CT system during image-guided interventional oncology procedures",[128,29],[672],"spectral CT","2025-12-18",{"date":675,"type":44},"2025-12-26",{"date":677,"type":44},"2025-02-01",{"date":679,"type":21},"2026-09-01",{"name":681,"class":114},"Palo Alto Veterans Institute for Research",{"id":683,"slug":684,"hasResults":12,"nctId":685,"briefTitle":686,"officialTitle":687,"acronym":688,"eligibilityCriteria":689,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":690,"targetDuration":4,"studyType":87,"phases":691,"briefSummary":692,"conditions":693,"keywords":696,"overallStatus":163,"whyStopped":4,"lastUpdateSubmitDate":701,"lastUpdatePostDateStruct":702,"startDateStruct":704,"completionDateStruct":705,"leadSponsor":707,"locationsCount":76},"100614895","stereotactic-body-radiotherapy-with-continuous-tracking-for-primary-and-secondary-renal-cancer-100614895","NCT07285538","Stereotactic Body RadioTherapy With Continuous Tracking for Primary and Secondary Renal Cancer","A Prospective Interventional Study of Stereotactic Body RadioTherapy (SBRT) With Continuous Tracking for Inoperable Patients With Primary and Secondary Renal Cancer (SBRTRC)","SBRTRC","Inclusion Criteria:\n\n1. Histological or clinical diagnosis of primary or secondary kidney tumors\n2. Patients aged ≥18 years\n3. Signed informed consent\n4. Tumor up to 10 cm in the greatest diameter (sum of diameters in case of multiple lesions)\n5. PS (ECOG) ≤2\n6. No prior local radiotherapy\n7. Fertile women using contraception methods previously initiated (a pregnancy test will be prescribed)\n\nExclusion Criteria:\n\n1. Patients aged \\\u003C 18 years\n2. Tumors \\> 10 cm\n3. PS ECOG ≥3\n4. Psychiatric or other disorders that may prevent the patient from signing informed consent\n5. Previous invasive cancer, except for skin cancer (excluding melanoma) unless the patient has been disease-free for at least 3 years (e.g., carcinoma in situ of the oral cavity or bladder)\n6. Pregnant women\n7. Collagen diseases\n8. Sjogren's syndrome",{"count":638,"type":21},[89],"This is a prospective, interventional, monocentric, clinical study of Stereotactic Body Radiation Therapy (SBRT) for primary or secondary renal tumors, delivering from 25-26 Gy\u002F1 fraction to 42-48 Gy\u002F3-4 fractions or 40-50 Gy\u002F5 fractions (standard prescriptions for the internationl guidelines, according to tumor size), using a robotic accelerator -CyberKnife® (Accuray, Sunnyvale, CA)-, with fiducial-tracking, to observe the acute and late toxicity reduction (as primary objectives), due to the maximum precision of the treatment. Secondary objectives are Local Relpase-Free Survival (LRFS), Regional Relapse-Free Survival (RRFS), Distant Metastasis-Free Survival (DMFS), Disease-Free Survival (DFS), Cancer Specific Survival (CSS), Overall Survival (OS) and Quality-of-Life (QoL). A total of 60 participants are expected to be enrolled over four years, and the follow-up of enrolled patients will be three years.",[29,694,695],"Renal Secondary Cancer","Stereotactic Body Radiotherapy",[697,698,585,699,700],"Renal primary tumors","Renal secondary tumors","stereotactic ablative radiotherapy","Renal toxicity","2025-12-12",{"date":703,"type":44},"2025-12-16",{"date":654,"type":21},{"date":706,"type":21},"2033-01-15",{"name":233,"class":114},{"id":709,"slug":710,"hasResults":12,"nctId":711,"briefTitle":712,"officialTitle":713,"acronym":4,"eligibilityCriteria":714,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":715,"targetDuration":4,"studyType":87,"phases":717,"briefSummary":718,"conditions":719,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":721,"lastUpdatePostDateStruct":722,"startDateStruct":724,"completionDateStruct":726,"leadSponsor":728,"locationsCount":76},"100469058","decision-aid-da-for-renal-patients-100469058","NCT05387863","Decision Aid (DA) for Renal Patients","Evaluation of a Decision Aid in the Treatment Planning of Small Renal Tumors","Inclusion Criteria:\n\n* Male and female post-op and pre-op patients, ages 18 and older, diagnosed with a localized renal tumor up to 4 cm in diameter.\n* Patients scheduled for standard-of-care clinical exams with the NYU Urology Department\n\nExclusion Criteria:\n\n* Stage IV cancer of any type\n* Inability to provide informed consent\n* Vulnerable subjects will not be recruited",{"count":716,"type":21},40,[89],"The objective of this study is to understand how patients make decisions about treating their kidney masses, and to identify key values and preferences for treating their kidney masses. The study team will develop a decision aid (DA) using the decision-analytic model to communicate personalized benefit\u002Fharm estimates to patients and promote patient-centered treatment of renal tumors.",[720,29],"Kidney Tumor","2025-11-28",{"date":723,"type":44},"2025-12-02",{"date":725,"type":44},"2022-09-12",{"date":727,"type":21},"2026-09",{"name":729,"class":114},"NYU Langone Health",{"id":731,"slug":732,"hasResults":12,"nctId":733,"briefTitle":734,"officialTitle":735,"acronym":736,"eligibilityCriteria":737,"healthyVolunteers":16,"sex":738,"minAge":84,"maxAge":739,"enrollmentInfo":740,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":741,"conditions":742,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":744,"lastUpdatePostDateStruct":745,"startDateStruct":747,"completionDateStruct":749,"leadSponsor":751,"locationsCount":76},"100595833","women-with-isolated-acute-cystitis-and-macroscopic-hematuria-is-further-investigation-needed-100595833","NCT07037589","Women With isoLated acUte cyStitis and Macroscopic Hematuria. Is Further Investigation Needed?","Women With isoLated acUte cyStitis and Macroscopic Hematuria. Is Further Investigation Needed? A Prospective Multicenter Study. BLUSH Trial","BLUSH","Inclusion Criteria:\n\n1. Women ≥50 years of age.\n2. Macroscopic hematuria.\n3. Presenting for evaluation within the SCP for macroscopic hematuria.\n4. Ability to provide informed consent.\n\nExclusion Criteria:\n\n1. Prior diagnosis of bladder cancer, renal cancer, or upper tract urothelial carcinoma (UTUC).\n2. Cognitive impairment preventing informed consent.\n3. Ongoing or recent treatment for urological malignancy.\n4. Serious comorbidities affecting participation or safety.\n5. Pregnant women.","FEMALE","110 Years",{"count":270,"type":21},"This prospective multicenter observational study evaluates whether women ≥50 years with isolated acute hemorrhagic cystitis (AHC) and macroscopic hematuria require full malignancy workup. All participants undergo standard diagnostics (cystoscopy, CT urography, cytology), with 12-month follow-up for cancer detection. The aim is to identify low-risk patients where invasive investigations may be safely avoided.",[503,743,65,92,29],"Acute Cystitis With Hematuria","2025-11-17",{"date":746,"type":44},"2025-11-21",{"date":748,"type":44},"2025-10-13",{"date":750,"type":21},"2027-08-30",{"name":752,"class":753},"Vastra Gotaland Region","OTHER_GOV"]